5-HTP: Evidence, Safety and Interactions

What the Evidence Shows for 5-HTP

Human clinical trial evidence evaluating 5-HTP for depressive symptoms is limited in scale. A systematic review conducted by Shaw, Turner, and Del Mar for the Cochrane Database of Systematic Reviews evaluated the efficacy of both tryptophan and 5-hydroxytryptophan for depression. Their literature search in 2001 examined 108 studies, and an updated search in 2004 identified three additional candidates. Only two trials met the review's inclusion criteria. Across both qualifying trials, a total of only 64 human patients were enrolled.

When the authors pooled the data from those two trials, the statistical analysis suggested that the precursors were more effective than placebo, showing an odds ratio of 4.10 with a 95 percent confidence interval spanning from 1.28 to 13.15. The review authors concluded that this evidence is of insufficient quality to be conclusive. Further research addressing both efficacy and safety is required before widespread public adoption could be recommended. The authors also noted that antidepressants with proven efficacy and safety limit the clinical usefulness of 5-HTP and tryptophan.

Side effects reported in the reviewed trials were dizziness, nausea, and diarrhoea. You can read the complete analysis in the Cochrane review of tryptophan and 5-HTP for depression.

What 5-HTP and 5-HT Mean in the Body

5-HT and 5-HTP are two steps on the path from tryptophan to serotonin. The term 5-HT is the standard scientific abbreviation for 5-hydroxytryptamine, which is the chemical name for serotonin. In human biochemistry, 5-hydroxytryptophan (5-HTP) acts as the direct intermediate between tryptophan and the finished neurotransmitter serotonin. Turner, Loftis, and Blackwell wrote the 2006 review of 5-HTP supplementation. It examines how much 5-HTP the body makes from tryptophan. The authors also evaluated how peripheral enzyme blockers such as carbidopa change how much reaches the brain.

Safety Concerns: Serotonin Syndrome and EMS

The main safety concerns are serotonin syndrome and EMS. The first, flagged in the 2006 pharmacological review, is serotonin syndrome, which comes from possible serotonin excess. Combining an exogenous serotonin precursor like 5-HTP with prescription medications that alter serotonin reuptake or degradation presents a recognized theoretical risk. Prescriptions carrying this mechanism include selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase (MAO) inhibitors. Anyone taking prescription antidepressants or other serotonergic medications must consult their prescribing clinician before considering precursor supplements.

The second major historical safety issue is eosinophilia-myalgia syndrome (EMS). In 1989, L-tryptophan was withdrawn from the market following an outbreak of eosinophilia-myalgia syndrome that was tied to a contaminated product. A toxicology evaluation by Das, Bagchi, Bagchi, and Preuss presented the 2004 safety review of 5-HTP. These authors reviewed roughly twenty years of global consumer use and reported that no definitive cases of 5-HTP toxicity had emerged, with the exception of a single unresolved medical case involving a Canadian woman.

The authors of the 2004 paper analysed several 5-HTP sources and concluded that the material lacked the specific toxic chemical contaminants previously discovered in the 1989 L-tryptophan outbreak. They also disputed the scientific validity of a minor chromatographic peak, termed peak X, arguing that claims of its toxicity lack credibility. The question is not fully settled: the 2006 review still lists EMS and serotonin syndrome as main safety concerns.

Limits of the Evidence for 5-HTP

The available scientific literature on 5-HTP leaves one question open: the two usable Cochrane trials (64 patients) cannot settle whether 5-HTP works, and the same pooled result that favoured it over placebo was judged of insufficient quality to be conclusive.

Turner and colleagues reviewed preclinical and double-blind placebo-controlled clinical evidence for antidepressant effects alongside safety concerns. Antidepressants with proven efficacy and safety limit the clinical usefulness of 5-HTP and tryptophan.

If Low Mood or Tiredness Follows Your Cycle

For readers experiencing cycle-related low mood and tiredness, see our guide on fatigue before period.

None of the sources used for this page tested 5-HTP for premenstrual symptoms, so this page makes no claim that it helps with them. For sleep and stress, see our guides on cortisol and sleep and melatonin dosage. Other supplements are covered in longevity supplements.

What to Do With This Information

Dietary supplements sold in retail stores are not evaluated or approved by the FDA for clinical effectiveness before they are marketed to consumers. This page gives no dose, and none of the sources used here support claims that 5-HTP treats body weight, sleep or premenstrual syndrome. Adverse reactions reported in clinical trials include dizziness, nausea, and diarrhoea.

Decisions regarding whether to take 5-HTP require a personalized evaluation by a qualified medical clinician. Medical consultation is critical for individuals taking antidepressants, women who are pregnant or breastfeeding, or those taking other medicines. Discuss your symptoms and current prescription regimen with your licensed healthcare provider before introducing 5-HTP or any other supplement.